The DOI matches its Crossref record; 244 of the 249 references it cites were found in a registry or an index; 263 of the 340 sources its claims cite were checked for support.
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Open accessAbstract
Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide, with a significant impact on public health. Current treatment options include surgery, chemotherapy, radiotherapy, molecular-targeted therapy, and immunotherapy. Despite advancements in these therapeutic modalities, resistance remains a significant challenge, often leading to treatment failure, poor progression-free survival, and cancer recurrence. Mechanisms of resistance in CRC are multifaceted, involving genetic mutations, epigenetic alterations, tumor heterogeneity, and the tumor microenvironment. Understanding these mechanisms at the molecular level is crucial for identifying novel therapeutic targets and developing strategies to overcome resistance. This review provides an overview of the diverse mechanisms driving drug resistance in sporadic CRC and discusses strategies currently under investigation to counteract this resistance. Several promising strategies are being explored, including targeting drug transport, key signaling pathways, DNA damage response, cell death pathways, epigenetic modifications, cancer stem cells, and the tumor microenvironment. The integration of emerging therapeutic approaches that target resistance mechanisms aims to enhance the efficacy of current CRC treatments and improve patient outcomes.
Overview
CoChat Summary
TL;DR
This review summarizes the diverse mechanisms driving drug resistance in sporadic colorectal cancer (CRC)—including drug transport/metabolism, signaling pathway alterations, DNA damage response and cell death defects, epigenetic changes, tumor heterogeneity/CSCs/DTPs, and the tumor microenvironment—and discusses therapeutic strategies under investigation to overcome it. It concludes that combination approaches targeting multiple resistance mechanisms, guided by molecular profiling, hold the most promise.
Key findings
- Drug resistance in CRC is multifactorial and can be intrinsic or acquired; recurrence occurs in 30–40% of patients who complete treatment, mostly within the first 2–3 years, and resistance has been reported to develop in nearly all CRC patients. Mechanisms include ABC transporter–mediated efflux (PGP/MDR1, BCRP, MRP1/2), altered drug metabolism (GSTs, UGTs, CYPs), secondary mutations/alternative pathway activation (EGFR, RAS/BRAF, PI3K/AKT/mTOR, HER2/MET), enhanced DNA damage response, defective apoptosis/autophagy, epigenetic alterations, CSCs, EMT, DTPs, and the TME.
- Key molecular features: APC mutated in ~80% of CRCs, KRAS ~40%, BRAF 10–15%, TP53 50–60%, SMAD4 ~15%, PIK3CA ~20%; CIN accounts for ~85% of sporadic CRCs, MSI ~15%, CIMP ~20%. Consensus molecular subtypes: 87% of samples assigned to CMS1–4 (CMS1 14%, CMS2 37%, CMS3 13%, CMS4 23%), with 13% mixed features.
- Strategies under investigation include targeting ABC transporters (e.g., miRNA mimics miR-133b, miR-142-3p, miR-297, miR-522; nanomedicine), EGFR and alternative pathways (Sym004, anti-HER2/anti-MET, KRAS-G12C inhibitors sotorasib/adagrasib, BRAF+EGFR+MEK combinations), DDR (PARP, ATM, WEE1 inhibitors), cell death pathways (BH3 mimetics, IAP antagonist TL32711, chloroquine/hydroxychloroquine, ferroptosis inducers RSL3/erastin), epigenetic therapies (DNMT, HDAC, EZH2, KDM1A/KDM4 inhibitors; ncRNA modulation), CSCs (LGR5 antibody–drug conjugates, MCLA-158, BiTEs, oncolytic viruses, Wnt/Notch/Hh inhibition, differentiation therapy), and the TME (anti-angiogenic agents, HIF inhibitors, hypoxia-activated prodrug evofosfamide, ECM/LOX targeting, CAF targeting, ICIs, CAR-T cells).
- The review concludes that CRC heterogeneity and multiple resistance mechanisms make it unlikely that one therapy can eliminate all CRC cells; combination therapies and precision medicine guided by genomic, epigenomic, and molecular profiling are emphasized.
Methods
- Design: narrative review providing an overview of drug resistance mechanisms in sporadic CRC and strategies under investigation to counteract resistance.
- Data: published literature, with references cited throughout; no primary patient data or experimental study is reported.
- Main analysis: narrative synthesis of mechanisms and therapeutic approaches; no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described.
Limitations
- Stated: the paper does not include an explicit limitations section for the review itself.
- Evident: as a narrative review, it lacks a described systematic search strategy, inclusion/exclusion criteria, and quantitative synthesis, so selection and interpretation of evidence may be subject to bias.
- Evident: the scope is sporadic CRC, and many discussed strategies are preclinical or still under investigation, with clinical utility and biomarker-based patient selection not yet established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
219 Valid · 5 Not valid · 40 Not checked · 59 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Polymeric polylactide-co-glycolic acid (PLGA) NPs were also shown to increase the cytotoxicity of chemotherapy drugs, such as 5-FU and irinotecan, in CRC cell lines [113,114].”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 4. Strategies to Overcome Drug Resistance > 4.1. Targeting ABC Membrane Transporters
What the sources say
- Not checked — no full text of the sourcecites [113] Emami, 2018, PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan, Pharm. Dev. Technol. source
- Disputedcites [114] Ghasemi Toudeshkchouei, M., Zahedi, P., and Shavandi, A. (2020). Microfluidic-Assisted Preparation of 5-Fluorouracil-Loaded PLGA Nanoparticles as a Potential System for Colorectal Cancer Therapy. Materials, 13. sourceExperimental — accuracy not yet measured
In Results and Discussion §3.5 (page unavailable), the paper reports more cell death with neat 5-FU than with 5-FU-loaded PLGA nanoparticles in both CRC cell lines—the opposite of increased cytotoxicity relative to the free drug. The study evaluates 5-FU, not irinotecan. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“CRC is commonly associated with mutations in key driver genes including APC, KRAS, BRAF, TP53, SMAD4, and PIK3CA [12].”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 1. Introduction > 1.3. Genetic Mutations and Associated Molecular Pathways
What the sources say
- Supportedcites [12] Carethers, 2015, Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer, Gastroenterology source
The sections on non-hypermutated sporadic CRCs describe APC, KRAS, PIK3CA, TP53 and SMAD4 as altered genes, including mutations and, for some, loss of heterozygosity. The section on hypermutated sporadic CRCs identifies BRAF mutation as common in sporadic MSI-H CRCs. No page numbers are provided in the supplied passages. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“CRC presents different types of epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNA (ncRNA)-associated changes [21,23].”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 1. Introduction > 1.4. Epigenetic Alterations and Associated Molecular Pathways
What the sources say
- Supportedcites [21] Jung, 2020, Epigenetics of colorectal cancer: Biomarker and therapeutic potential, Nat. Rev. Gastroenterol. Hepatol. source
The Principles of epigenetics section identifies DNA methylation, histone modifications, and ncRNA regulators as implicated in CRC. The Introduction likewise lists these as topics of epigenetic alteration and regulation in CRC. (LLM, conf=0.95)
- Supportedcites [23] Sadida, 2024, Epigenetic modifications: Key players in cancer heterogeneity and drug resistance, Transl. Oncol. source
The review’s “Epigenetic mechanisms in cancer” section identifies DNA methylation, histone modification, and non-coding RNA as epigenetic mechanisms. Its discussion of colorectal cancer also gives examples involving methylation and histone acetylation, and links miR-126 expression to colorectal cancer. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Reduced drug influx is a common mechanism of resistance, often resulting from decreased expression of transporters responsible for drug uptake, such as membrane solute carrier (SLC) family proteins [43].”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 3. Mechanisms of Drug Resistance > 3.1. Drug Transport and Metabolism
What the sources say
- Supportedcites [43] Puris, E., Fricker, G., and Gynther, M. (2023). The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy. Pharmaceutics, 15. source
Section 4 states that insufficient anticancer drug delivery into cancer cells can result from down-regulation of membrane influx transporters. Section 6 identifies acquired down-regulation of SLC transporters responsible for anticancer drug uptake as a cause of ineffective treatment. The paper frames this as a mechanism of anticancer drug resistance, without quantifying how common it is. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the tumor microenvironment (TME) plays a significant role in mediating resistance.”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 3. Mechanisms of Drug Resistance
What the sources say
- Supportedcites [41] Wang, Q., Shen, X., Chen, G., and Du, J. (2022). Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. Cancers, 14. source
Section 9, “Tumor Microenvironment,” states that TME components can act as therapeutic barriers and provide a sanctuary in which tumor cells escape drug-mediated death and develop resistance. The Conclusions also explicitly identify the TME as a focus in drug resistance. The provided passages do not give page numbers. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
165 more claims · 118 with their cited sources checked
Create a free account to see all 323 claims and to verify the 3 references still open.
- It may state two separate claims as one. 130
- Probably not a substantial claim. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the PIK3CA gene, which encodes the p110α catalytic subunit of Class I PI3K, occur in approximately 15–20% of colorectal cancers and represent one of the most common alterations affecting this pathway [17,18].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF is a serine/threonine protein kinase (signal transduction protein) and activating mutations in it accounts for around ten to fifteen percent of CRCs, mainly the BRAF V600E—a point mutation and a biomarker of poor prognosis [18,20,21,22].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutations in RAS, importantly, the KRAS-mutated tumors, are associated with around forty percent of CRCs [12,18,19], while NRAS is less frequent but remains a clinically relevant contributor to tumor heterogeneity.”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 2. Therapeutic Approaches for Colorectal Cancer > 2.2. Targeted Therapies
“Anti-EGFR therapies, such as EGFR tyrosine kinase inhibitors cetuximab and panitumumab, block or slow down the growth of tumor cells.”
§ Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer > 4. Strategies to Overcome Drug Resistance > 4.2. Targeting EGFR and Alternative Pathways
“Targeting molecules involved in these resistance mechanisms would help to overcome resistance to anti-EGFR monoclonal antibody (mAb) therapies like cetuximab and panitumumab.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Furthermore, EGF-targeted 5-FU-loaded PLGA NPs were developed to selectively target CRC cells expressing high levels of EGFR and showed higher rates of cytotoxicity and apoptosis and lower rates of tumor growth compared to non-targeted or non-NP treatments [115].”
Cited work 10.1186/s12885-020-06803-7 · retracted 2026-08-22 · notice 10.1186/s12885-026-16805-6 · this paper published 2025-02-25
Citations
Cites
1 retracted
Wu, P., Zhou, Q., Zhu, H., Zhuang, Y., & Bao, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-06803-7 · Cited by 97 · cited 1×
“Furthermore, EGF-targeted 5-FU-loaded PLGA NPs were developed to selectively target CRC cells expressing high levels of EGFR and showed higher rates of cytotoxicity and apoptosis and lower rates of tumor growth compared to non-targeted or non-NP treatments [115].”
RetractedBray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111 · cited 1×
“The TME is also characterized by chronic inflammation, which is linked to tumor cell proliferation, survival, and metastasis [94].”
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931 · cited 1×
“Epithelial–mesenchymal transition is a cellular process that involves switching from an epithelial to a mesenchymal cell phenotype and occurs during normal physiological processes, such as development and wound healing [73].”
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533 · cited 2×
“The incidence rates for CRC in the United States from 2016 to 2020 were 35.3 per 100,000 people, with 40.7 in 100,000 for men and 30.6 per 100,000 for women [1].”
InfluentialMolecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“During EMT, cells downregulate expression of the epithelial cell adhesion protein E-cadherin and upregulate expression of EMT transcription factors, including SNAIL, ZEB, and TWIST families, leading to a loss of cell–cell adhesion and polarity and a gain in cell motility [74].”
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 1×
“Stromal cells within the TME are attractive therapeutic targets because they are genetically stable with reduced risk of developing resistance [223].”
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 1×
“Sequential mutations in driver genes—known as the adenoma–carcinoma sequence—are thought to occur at the transitions from normal epithelium to pre-malignant tumor to malignant tumor [19].”
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 2×
“…inconsistencies among CRC subtype classifications, an international consortium formed across expert groups and developed a gene expression-based classification system based on six different published CRC subtyping platforms to systematically assign CRC consensus molecular subtypes (CMS) [28].”
Ferroptosis: past, present and future
Li, J., Cao, F., Yin, H.-L., Huang, Z.-J., Lin, Z.-T., Mao, N., Sun, B., & Wang, G. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2298-2 · Cited by 4,171 · cited 1×
“Factors that induce ferroptosis can affect glutathione peroxidase (GPX) activity through different pathways, resulting in decreased cellular antioxidant capacity and accumulation of lipid ROS, eventually leading to oxidative damage and cell death [153].”
Colorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733 · cited 3×
“While CRC incidence rates have gone down overall since their peak in 1985, the prevalence of CRC has been rising in younger adults (20–49 years) for decades [2].”
InfluentialThe molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809 · cited 1×
“Epigenetic modifications can alter gene expression without permanently changing the underlying DNA sequence [22] and are influenced by aging and environmental and lifestyle factors.”
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · cited 1×
“Drug-tolerant persisters (DTPs) are a small subpopulation of cells within tumors that can survive anticancer drug treatment by entering a transient quiescent or slow cycling state (dormancy) [78].”
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769 · cited 2×
“Like normal adult stem cells, CSCs can self-renew indefinitely and differentiate into non-stem cell progeny (multipotent), thereby generating the majority of cancer cells in a tumor [68].”
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866 · cited 3×
“While various ABC transporter inhibitors have been shown to sensitize drug-resistant colon cancer cells to chemotherapy drugs in experimental models [98–101], the development of PGP as a therapeutic target for cancer in general has not been successful clinically [42].”
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757 · cited 2×
“It is an alkylating agent that damages DNA and inhibits DNA synthesis [30,31].”
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612 · cited 1×
“Furthermore, hypoxia promotes self-renewal by activation of Wnt and Notch signaling pathways and embryonic stem cell transcription factors, and it modulates differentiation of tumor cells and tumor-associated stromal cells [86–88].”
Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. H., & Watanabe, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.65 · Cited by 1,563 · cited 5×
“For advanced CRC cases, symptoms can include rectal bleeding, blood in stool, change in bowel habits, abdominal pain, abdominal mass, bowel obstruction, constipation, diarrhea, iron-deficiency anemia, weight loss, and fatigue [7,8].”
InfluentialEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 1×
“However, the triple combination of BRAF, EGFR, and MEK inhibition has shown higher response rates and improved efficacy in patients with BRAF -mutant CRC [238,239].”
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206 · cited 1×
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187 · cited 3×
“Dense ECM, abnormal vasculature, and an acidified environment all contribute to decreased drug penetration [83].”
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148 · cited 1×
“Myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immune cells from the myeloid lineage, are a major component of the immunosuppressive TME [93].”
Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids
Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., Watanabe, T., Kanai, T., & Sato, T. (2015) · Nature Medicine · doi:10.1038/nm.3802 · Cited by 1,135 · cited 1×
“Invasive and metastatic transformation likely involves additional alterations, such as chromosomal instability and other genetic and epigenetic modifications [20].”
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043 · cited 2×
“It is an alkylating agent that damages DNA and inhibits DNA synthesis [30,31].”
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977 · cited 1×
“For example, inhibiting lysyl oxidase (LOX) family enzymes, which are involved in the crosslinking of ECM proteins collagen and elastin, can reduce matrix stiffness and improve drug delivery to tumor cells [219].”
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962 · cited 2×
“In addition, several other ECM components, such as fibronectin, hyaluronan, TGF-β , integrins involved in mechanotransduction, and other sensors of matrix stiffness, are being studied as potential therapeutic targets in various cancers, including CRC [218].”
Sawicki, T., Ruszkowska, M., Danielewicz, A., Niedźwiedzka, E., Arłukowicz, T., & Przybyłowicz, K. E. (2021) · Cancers · doi:10.3390/cancers13092025 · Cited by 921 · cited 2×
“Most sporadic CRCs start as a benign growth of tissue on the mucous layer of the colon or rectum called a polyp, which can become cancerous over time if left untreated [7].”
Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, D. J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., et al. (2022) · Cancers · doi:10.3390/cancers14071732 · Cited by 920 · cited 3×
“There are many factors that can increase the risk for CRC, including both non-modifiable biological risk factors and modifiable lifestyle risk factors [5].”
InfluentialEpigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813 · cited 10×
“There are several different classes of drugs that inhibit enzymes responsible for epigenetic modifications, including DNA methyltransferases (DNMTs), histone deacetylases (HDACs), histone methyltransferases (HMTs), and histone demethylases (HDMs) [21,66].”
InfluentialEpigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Okugawa, Y., Grady, W. M., & Goel, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.011 · Cited by 782 · cited 1×
“Aberrant DNA hypermethylation occurs in the promoter regions of many tumor suppressor genes, including APC , CDKN2A , MLH1 , and CDH1 [25].”
RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer
Sui, X., Zhang, R., Liu, S., Duan, T., Zhai, L., Zhang, M., Han, X., Xiang, Y., Huang, X., Lin, H., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01371 · Cited by 703 · cited 1×
“For instance, the ferroptosis inducer RSL3 (small molecule inhibitor of GPX4) initiated ROS accumulation and cell death in multiple CRC cell lines [154].”
(2003) · PubMed · Cited by 624
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614
Georgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609 · cited 1×
“Additional preclinical studies showed that repolarizing TAMs enhanced T-cell-mediated anti-tumor immune response and improved the efficacy of ICIs in CRC tumors [234,235].”
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592 · cited 1×
“However, the triple combination of BRAF, EGFR, and MEK inhibition has shown higher response rates and improved efficacy in patients with BRAF -mutant CRC [238,239].”
Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y. (2018) · Gastroenterology Research · doi:10.14740/gr1062w · Cited by 553 · cited 2×
“Within the colon, most tumors develop in the distal colon (~70%), which includes the descending colon, sigmoid colon, and distal one-third of the transverse colon [6].”
Dual role of autophagy in hallmarks of cancer
Singh, S. S., Vats, S., Chia, A. Y.-Q., Tan, T. Z., Deng, S., Ong, M. S., Arfuso, F., Yap, C. T., Goh, B. C., Sethi, G., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0046-6 · Cited by 542 · cited 1×
“Normally, autophagy plays a tumor suppressive role by preventing the accumulation of misfolded proteins, damaged organelles, and reactive oxygen species (ROS) [54].”
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527 · cited 1×
“In addition, EMT-induced CRC cells interact differently with their microenvironment, leading to enhanced ECM remodeling and immune evasion [77].”
Clinical implications of intratumor heterogeneity: challenges and opportunities
Ramón y Cajal, S., Sesé, M., Capdevila, C., Aasen, T., De Mattos-Arruda, L., Diaz-Cano, S. J., Hernández-Losa, J., & Castellví, J. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01874-2 · Cited by 514 · cited 1×
“…existence of different molecular profiles between tumors from different patients, whereas intra-tumoral heterogeneity refers to the presence of different molecular profiles within a single tumor due to tumor cell subpopulations that have distinct genetic, epigenetic, and phenotypic profiles [67].”
Self-renewal as a therapeutic target in human colorectal cancer
Kreso, A., van Galen, P., Pedley, N. M., Lima-Fernandes, E., Frelin, C., Davis, T., Cao, L., Baiazitov, R., Du, W., Sydorenko, N., et al. (2014) · Nature Medicine · doi:10.1038/nm.3418 · Cited by 500 · cited 1×
“For instance, treatment of patient-derived CRC xenografts with a small molecule inhibitor of BMI-1 (a subunit of the Polycomb Repressive Complex 1 that functions as an epigenetic chromatin modifier) resulted in loss of colorectal CSCs and long-term impairment of tumor growth [203].”
Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy
Rehman, S. K., Haynes, J., Collignon, E., Brown, K. R., Wang, Y., Nixon, A. M. L., Bruce, J. P., Wintersinger, J. A., Singh Mer, A., Lo, E. B. L., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.018 · Cited by 495 · cited 1×
“For instance, CRC DTPs were found to induce an embryonic survival phenotype (diapause) that activates autophagy, in response to the chemotherapy drug irinotecan [81].”
Self-citationCalabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487 · cited 1×
“Furthermore, PARP inhibitors enhanced the anticancer activity of chemoradiation in CRC cell lines in vitro and in vivo [136–138].”
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer
Carethers, J. M., & Jung, B. H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.047 · Cited by 483 · cited 6×
“MSI accounts for ~15% of sporadic CRCs [12].”
InfluentialEffective drug combinations in breast, colon and pancreatic cancer cells
Jaaks, P., Coker, E. A., Vis, D. J., Edwards, O., Carpenter, E. F., Leto, S. M., Dwane, L., Sassi, F., Lightfoot, H., Barthorpe, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04437-2 · Cited by 469 · cited 1×
“A recent study systematically evaluated clinically relevant two-drug combinations in cancer cell lines and identified synergistic effects between chemotherapy agents and drugs targeting apoptotic signaling or cell cycle inhibitors in distinct molecular subpopulations [236].”
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455 · cited 1×
“Indeed, results from several preclinical and clinical studies indicate that dual pharmacological targeting of MAPK and PI3K pathways may be an effective strategy to inhibit the growth of CRC cells, regardless of KRAS or PI3K mutational status [127–131].”
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433 · cited 1×
“Since epigenetic drugs modulate various components of the TME, they are also being tested in combination with immunotherapy (e.g., ICIs) for their ability to increase tumor antigen expression, processing, and presentation, thereby aiming to reverse immune evasion [157].”
Molecular pathological classification of colorectal cancer
Müller, M. F., Ibrahim, A. E. K., & Arends, M. J. (2016) · Virchows Archiv · doi:10.1007/s00428-016-1956-3 · Cited by 432 · cited 1×
“This genome-based molecular subtyping depends on features of chromosomal instability (CIN), microsatellite instability (MSI), and CpG island methylator phenotype (CIMP) [27].”
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431
Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910260 · Cited by 402 · cited 1×
“Increased levels of cytokines and growth factors in the TME can activate cell proliferation and survival signaling pathways in CRC cells (e.g., MAPK and PI3K/AKT) [84].”
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381 · cited 4×
“Defects in apoptosis are common in CRC and are mainly due to inactivating mutations in TP53 , and increased expression of anti-apoptotic proteins (e.g., BCL-2, BCL-XL) or decreased expression of pro-apoptotic proteins (e.g., BAX, BIM) [47].”
InfluentialWang, H., Tian, T., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168470 · Cited by 364 · cited 2×
“One potential approach is to modulate the colorectal TME by inhibiting signaling molecules or pathways that promote the recruitment of monocytes and macrophages to the tumor site, such as the CCL2/CCR2 and CSF-1/CSF-1R pathways [41,95].”
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
Li, C., Xu, X., Wei, S., Jiang, P., Xue, L., & Wang, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001341 · Cited by 360
Targeting Cancer Cell Dormancy
Recasens, A., & Munoz, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.12.004 · Cited by 356 · cited 2×
“Notably, DTPs do not have permanent genetic mutations that confer resistance [79].”
(2001) · PubMed · Cited by 350
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339 · cited 10×
“Activation of survival pathways can promote cell survival and proliferation in the presence of DNA-damaging agents [49].”
InfluentialCD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440169 · Cited by 338 · cited 1×
“For instance, CAR-T cells currently under development for targeting colorectal CSCs include CD133, EpCAM-, or CD166-directed CAR-T cells [229–232].”
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316 · cited 1×
“In CRC cells, Wnt pathway inhibition has been demonstrated to inhibit cell proliferation, reduce tumor-initiating cell numbers, and impair tumor growth in CRC xenograft models [190–193].”
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306 · cited 1×
“In addition, death receptor-targeted therapies (e.g., DR4/DR5 agonist antibodies) were shown to enhance the antitumor activity of chemotherapy drugs (5-FU, irinotecan) in CRC xenograft models [145–147].”
Hedgehog Signaling in Development and Homeostasis of the Gastrointestinal Tract
van den Brink, G. R. (2007) · Physiological Reviews · doi:10.1152/physrev.00054.2006 · Cited by 301
Arnold, C. N., Goel, A., & Boland, C. R. (2003) · International Journal of Cancer · doi:10.1002/ijc.11176 · Cited by 280 · cited 1×
“For example, hypermethylation of the tumor suppressor gene MLH1 can lead to resistance against 5-FU by preventing the recognition and repair of DNA damage [56].”
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258
Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012153 · Cited by 244 · cited 1×
“In addition, the epidermal growth factor receptor (EGFR)/RAS/MAPK signaling pathway is often constitutively activated, either through activation of signaling proteins RAS ( KRAS mutated in ~40% of CRCs) or RAF ( BRAF mutated in 10–15% of CRCs), which stimulates cell proliferation [13–15].”
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231 · cited 1×
“Antibodies targeting HER2, such as trastuzumab and pertuzumab, have shown promising activity in patients with HER2-positive metastatic CRC [119,120].”
Lombardo, Y., Scopelliti, A., Cammareri, P., Todaro, M., Iovino, F., Ricci–Vitiani, L., Gulotta, G., Dieli, F., de Maria, R., & Stassi, G. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.005 · Cited by 222 · cited 1×
“Other agents, including bone morphogenetic protein 4 (BMP4) and some HDAC inhibitors, have also been shown to promote differentiation of colorectal CSCs and increase their response to chemotherapy [207–209].”
Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy
Selvakumaran, M., Amaravadi, R. K., Vasilevskaya, I. A., & O'Dwyer, P. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1542 · Cited by 221
Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H. (2020) · Cells · doi:10.3390/cells9020428 · Cited by 213 · cited 1×
“These include altered drug transport, e.g., overexpression of drug efflux pumps like ABC transporters, activation of cell survival signaling pathways such as PI3K/AKT, and deregulation of apoptotic pathways leading to resistance to apoptosis [76].”
Colorectal cancer screening—optimizing current strategies and new directions
Kuipers, E. J., Rösch, T., & Bretthauer, M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.12 · Cited by 211 · cited 1×
“CRC can be detected early, before it starts to cause symptoms through CRC screening modalities such as colonoscopy and stool-based tests [9].”
The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma
Das, P. K., Islam, F., & Lam, A. K. (2020) · Cells · doi:10.3390/cells9061392 · Cited by 210 · cited 2×
“In addition, CSCs can adapt in response to chemotherapy and radiotherapy by altering cell cycle checkpoints, by inducing cell cycle arrest (reversible quiescent G 0 state), or by efficient scavenging of ROS [70].”
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210 · cited 4×
“Moreover, inhibiting autophagy could also target therapy-resistant CSCs and DTPs, both of which often have upregulated autophagy pathways [80,152].”
InfluentialLópez de Andrés, J., Griñán-Lisón, C., Jiménez, G., & Marchal, J. A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00966-3 · Cited by 207
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
Leiphrakpam, P., & Are, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063178 · Cited by 193 · cited 2×
“Various drugs targeting this pathway are under investigation for CRC treatment, including pan-PI3K inhibitors, isoform-specific PI3K inhibitors, dual PI3K-mTOR inhibitors, Akt inhibitors, and mTOR inhibitors [126].”
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189 · cited 1×
“For example, in BRAF -mutated CRC, the response to single-agent BRAF inhibition is limited by EGFR-mediated adaptive feedback reactivation of MAPK signaling [237].”
Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer
Junttila, M. R., Mao, W., Wang, X., Wang, B.-E., Pham, T., Flygare, J., Yu, S.-F., Yee, S., Goldenberg, D., Fields, C., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7433 · Cited by 182 · cited 1×
“For example, LGR5-targeted antibody–drug conjugates were demonstrated to induce cytotoxicity in LGR5-high gastrointestinal cancer cells and decrease tumor size and proliferation in colon cancer xenograft models [181,182].”
Herpers, B., Eppink, B., James, M. I., Cortina, C., Cañellas-Socias, A., Boj, S. F., Hernando-Momblona, X., Glodzik, D., Roovers, R. C., van de Wetering, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00359-0 · Cited by 178 · cited 1×
“For instance, MCLA-158 (petosemtamab), a BsAb targeting both EGFR and LGR5, exhibited strong growth inhibition of patient-derived CRC organoids and orthotopic xenograft tumor models, including KRAS mutant CRCs resistant to cetuximab [184].”
Lutterbuese, R., Raum, T., Kischel, R., Hoffmann, P., Mangold, S., Rattel, B., Friedrich, M., Thomas, O., Lorenczewski, G., Rau, D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000976107 · Cited by 166 · cited 1×
“Additionally, EGFR-specific BiTEs were shown to lyse KRAS - and BRAF -mutated CRC cell lines in vitro and inhibit the growth of CRC xenograft tumors, while cetuximab was ineffective [188].”
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160 · cited 7×
“…or activating mutations, or MET gene amplification can lead to persistent RAS/MAPK signaling, thereby reducing the efficacy of anti-EGFR therapies [41]. activation of oncogenic/bypass signaling pathways, like Wnt/ β -catenin, Finally, the chronic activation of oncogenic/bypass signaling pathways,…”
InfluentialXu, K., Zhan, Y., Yuan, Z., Qiu, Y., Wang, H., Fan, G., Wang, J., Li, W., Cao, Y., Shen, X., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.017 · Cited by 160 · cited 1×
“Moreover, HIF-1 inhibitors have been shown to enhance the sensitivity of CRC cells to the cytotoxic effects of chemotherapy drugs like 5-FU and oxaliplatin [212–214].”
A novel 5-Fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes
Handali, S., Moghimipour, E., Rezaei, M., Ramezani, Z., Kouchak, M., Amini, M., Angali, K. A., Saremy, S., & Dorkoosh, F. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.128 · Cited by 154 · cited 1×
“Similarly, folic acid-targeted 5-FU-loaded liposomes were demonstrated to have greater efficacy in CRC cells in vitro and in vivo compared to liposomal 5-FU or free drug [116,117].”
Li, Y., Gan, Y., Liu, J., Li, J., Zhou, Z., Tian, R., Sun, R., Liu, J., Xiao, Q., Li, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00902-6 · Cited by 153 · cited 1×
“Targeting EZH2 may also be an effective strategy to overcome oxaliplatin resistance, since EZH2 was shown to promote oxaliplatin resistance in CRC cells, while EZH2 inhibitor suppressed tumor growth and sensitized CRC cells to oxaliplatin [172,173].”
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151 · cited 5×
“Key molecular mechanisms include DNA methylation, histone modifications, and ncRNA-associated changes [23].”
InfluentialAdams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148
MicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications
Strubberg, A. M., & Madison, B. B. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.027441 · Cited by 147
Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger, J. C., Ridge, N. A., Marszalowicz, G. P., Prajapati, P., Hersperger, A. R., Waldman, S. A., & Snook, A. E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0362 · Cited by 143 · cited 1×
“Several antigens being evaluated as candidates for anti-CRC CAR-T cell therapy have shown efficacy in CRC preclinical models, including carcinoembryonic antigen and guanylyl cyclase 2C [227,228].”
Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer
Kim, H.-A., Koo, B.-K., Cho, J.-H., Kim, Y.-Y., Seong, J., Chang, H. J., Oh, Y. M., Stange, D. E., Park, J.-G., Hwang, D., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61216 · Cited by 139 · cited 1×
“While inhibiting Notch signaling is an appealing strategy for CRC treatment, it does present certain challenges, as Notch1 was previously shown to counteract Wnt/ β -catenin signaling in mouse colon cancer cells [197].”
MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells
Shen, W.-W., Zeng, Z., Zhu, W.-X., & Fu, G.-H. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1037-x · Cited by 137
Bauer, J., Emon, M. A. B., Staudacher, J. J., Thomas, A. L., Zessner-Spitzenberg, J., Mancinelli, G., Krett, N., Saif, M. T., & Jung, B. (2020) · Scientific Reports · doi:10.1038/s41598-019-55687-6 · Cited by 133 · cited 1×
“Additionally, both increased matrix stiffness and hypoxia can induce EMT of CRC cells [89,90].”
Colon Cancer in Young Adults: Trends and Their Implications
Weinberg, B. A., & Marshall, J. L. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0756-8 · Cited by 132 · cited 1×
“The median age of diagnosis for CRC is 67; however, younger patients tend to present with a more advanced-stage disease compared to older patients [3].”
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130 · cited 4×
“This type of targeted therapy is only effective in the absence of mutations in , HER2-positive) ) for CRC with BRAF-V600E mutation, used in combination with EGFR inhibitor cetuximab (Figure 2) [14,34].”
InfluentialLGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0114 · Cited by 130 · cited 1×
“For example, LGR5-targeted antibody–drug conjugates were demonstrated to induce cytotoxicity in LGR5-high gastrointestinal cancer cells and decrease tumor size and proliferation in colon cancer xenograft models [181,182].”
Kaplan-Lefko, P. J., Graves, J. D., Zoog, S. J., Pan, Y., Wall, J., Branstetter, D. G., Moriguchi, J., Coxon, A., Huard, J. N., Xu, R., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11264 · Cited by 126
Symptomatic and Asymptomatic Colon Cancer Recurrence: A Multicenter Cohort Study
Duineveld, L. A. M., van Asselt, K. M., Bemelman, W. A., Smits, A. B., Tanis, P. J., van Weert, H. C. P. M., & Wind, J. (2016) · The Annals of Family Medicine · doi:10.1370/afm.1919 · Cited by 125 · cited 1×
“Furthermore, cancer recurrence occurs in 30–40% of patients who completed CRC treatment, with most recurrences happening in the first 2 to 3 years after initial treatment [40].”
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González‐Vallinas, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111781 · Cited by 123 · cited 1×
“This includes BiTEs and oncolytic viruses (discussed above), antitumor vaccines, and different types of adoptive cell transfer, such as chimeric antigen receptor (CAR) T cell therapy, tumor-infiltrating lymphocyte therapy, and T cell receptor therapy [37,38,226].”
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115 · cited 1×
“For example, a subset of CRC cell lines enriched for KRAS or BRAF mutations were found to be highly sensitive to the PARP inhibitor olaparib and also displayed functional deficiency in homologous recombination [133].”
Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1852-8 · Cited by 113 · cited 1×
“For instance, the HAP evofosfamide (also known as TH-302) was reported to enhance the anticancer activity of chemotherapy drugs in mouse xenograft models of various cancer types, including CRC [216].”
Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer
Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012798 · Cited by 112 · cited 1×
“Additional preclinical studies showed that repolarizing TAMs enhanced T-cell-mediated anti-tumor immune response and improved the efficacy of ICIs in CRC tumors [234,235].”
Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells
Safwat, M. A., Soliman, G. M., Sayed, D., & Attia, M. A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.076 · Cited by 109 · cited 1×
“For instance, gold nanoparticles have been used to effectively deliver various anti-CRC therapies to tumor cells, including chemotherapy drugs and anti-EGFR inhibitors, resulting in enhanced anticancer drug efficacy [110–112].”
Novel strategies to reverse chemoresistance in colorectal cancer
Ma, S., Zhang, J., Yan, T., Miao, M., Cao, Y., Cao, Y., Zhang, L., & Li, L. (2023) · Cancer Medicine · doi:10.1002/cam4.5594 · Cited by 108
Van Schaeybroeck, S., Kalimutho, M., Dunne, P. D., Carson, R., Allen, W., Jithesh, P. V., Redmond, K. L., Sasazuki, T., Shirasawa, S., Blayney, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.032 · Cited by 106
Abedi, F., Davaran, S., Hekmati, M., Akbarzadeh, A., Baradaran, B., & Moghaddam, S. V. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00764-6 · Cited by 102 · cited 1×
“For example, a synthesized dual drug-loaded pH/thermo-responsive hydrogel, which is a hydrophilic three-dimensional porous network, induced greater apoptotic cell death in CRC cells compared to the single drug-loaded carriers or free drugs [222].”
MicroRNA-520g Confers Drug Resistance by Regulating p21 Expression in Colorectal Cancer
Zhang, Y., Geng, L., Talmon, G., & Wang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620252 · Cited by 100 · cited 1×
“For instance, inhibition of miR-520g, which increases resistance to 5-FU by reducing p21 expression, was shown to sensitize colon cancer cells to 5-FU-induced apoptosis [176].”
Gao, R., Fang, C., Xu, J., Tan, H., Li, P., & Ma, L. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.01.005 · Cited by 99 · cited 1×
“In addition, different ncRNAs have been shown to contribute to resistance against 5-FU, oxaliplatin, and anti-EGFR therapies by various mechanisms [62–64].”
EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg9721 · Cited by 97
Usui, T., Sakurai, M., Umata, K., Elbadawy, M., Ohama, T., Yamawaki, H., Hazama, S., Takenouchi, H., Nakajima, M., Tsunedomi, R., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041098 · Cited by 96 · cited 1×
“Nevertheless, inhibiting Hh signaling in CRC cells has been shown to be effective in reducing cell viability and expression of CSC markers and may also enhance chemosensitivity at least in some cellular contexts [200–202].”
Butyrate-Induced Differentiation of Colon Cancer Cells Is PKC and JNK Dependent
Orchel, A., Dzierżewicz, Z., Parfiniewicz, B., Weglarz, L., & Wilczok, T. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2463-6 · Cited by 95
Drug resistance in colorectal cancer: An epigenetic overview
Luo, M., Yang, X., Chen, H.-N., Nice, E. C., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188623 · Cited by 94 · cited 7×
“There are several different classes of drugs that inhibit enzymes responsible for epigenetic modifications, including DNA methyltransferases (DNMTs), histone deacetylases (HDACs), histone methyltransferases (HMTs), and histone demethylases (HDMs) [21,66].”
InfluentialArena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5640 · Cited by 93 · cited 1×
“For instance, Sym004 is a mixture of two mAbs that bind distinct epitopes of EGFR and may have the potential to overcome acquired resistance due to EGFR mutations that inhibit the binding of conventional anti-EGFR antibodies to EGFR [118].”
miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2
Xu, K., Liang, X., Shen, K., Cui, D., Zheng, Y., Xu, J., Fan, Z., Qiu, Y., Li, Q., Ni, L., et al. (2012) · Biochemical Journal · doi:10.1042/bj20120386 · Cited by 93 · cited 1×
“Moreover, several studies have demonstrated that using miRNA mimics to increase the levels of specific miRNAs, such as miR-133b, miR-142-3p, miR-297, and miR-522, can increase the chemosensitivity of drug-resistant CRC cells [104–107].”
Martinelli, E., Troiani, T., D'Aiuto, E., Morgillo, F., Vitagliano, D., Capasso, A., Costantino, S., Ciuffreda, L. P., Merolla, F., Vecchione, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28236 · Cited by 92
Kao, T.-W., Bai, G.-H., Wang, T.-L., Shih, I.-M., Chuang, C.-M., Lo, C.-L., Tsai, M.-C., Chiu, L.-Y., Lin, C.-C., & Shen, Y.-A. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02724-y · Cited by 89 · cited 1×
“Additionally, as hypoxia is known to contribute to immunosuppression and ICI resistance, targeting hypoxia may also enhance the effectiveness of immunotherapies [215].”
Zhang, B.-L., Li, D., Gong, Y.-L., Huang, Y., Qin, D.-Y., Jiang, L., Liang, X., Yang, X., Gou, H.-F., Wang, Y.-S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.229 · Cited by 88
Cao, X., Yap, J. L., Newell-Rogers, M. K., Peddaboina, C., Jiang, W., Papaconstantinou, H. T., Jupitor, D., Rai, A., Jung, K.-Y., Tubin, R. P., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-42 · Cited by 87 · cited 1×
“For example, drugs targeting the BCL-2 family of proteins, such as BH3 mimetics, have been investigated for their ability to induce apoptosis in CRC cells [142,143].”
Pek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene · doi:10.1038/onc.2017.120 · Cited by 86
Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013474 · Cited by 85 · cited 1×
“For example, EpCAM/CD3 BiTEs eliminated CSCs in colon cancer cell lines and primary CSCs isolated from colon cancer patient samples and blocked CRC xenograft tumor growth [186,187].”
Hedgehog signaling pathway in colorectal cancer: function, mechanism, and therapy
Wu, C., Zhu, X., Liu, W., Ruan, T., & Tao, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139639 · Cited by 82 · cited 2×
“Aberrant activation of Hh signaling has been implicated in the pathogenesis of several types of cancer; however, its role in CRC is controversial and may depend in part on the CRC subtype and stage [198].”
Drug repurposing to overcome resistance to various therapies for colorectal cancer
Fong, W., & To, K. K. W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03134-0 · Cited by 81 · cited 3×
“…several existing drugs have been repurposed as potential anticancer agents, including some non-steroidal anti-inflammatory drugs (NSAIDs), statins (cholesterol lowering drugs), and metformin (anti-diabetic drug), which were shown to augment apoptosis and overcome chemoresistance in CRC cells [148].”
Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review
Roeder, F., Meldolesi, E., Gerum, S., Valentini, V., & Rödel, C. M. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01695-0 · Cited by 81
Fazzone, W., Wilson, P. M., LaBonte, M. J., Lenz, H., & Ladner, R. D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24403 · Cited by 80 · cited 2×
“…various studies suggest that inhibiting HDACs can overcome resistance to chemotherapy-induced DNA damage in CRC cells by different molecular mechanisms, such as downregulating thymidylate synthase gene expression or modifying chromatin condensation, and subsequently inducing cell death [58,59,165].”
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78 · cited 9×
“Activating mutations in the RAS/RAF/MEK/ERK signaling pathway downstream of EGFR generally confer resistance to anti-EGFR therapies; however, recent developments have led to new approaches for therapeutically targeting CRC with RAS or BRAF mutations [29].”
InfluentialOlsson, A., Nakhlé, J., Sundstedt, A., Plas, P., Bauchet, A.-L., Pierron, V., Bruetschy, L., Deronic, A., Törngren, M., Liberg, D., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0098-5 · Cited by 78 · cited 1×
“For instance, the small molecule immunotherapy drug tasquin-imod induced TAM phenotype switching from M2 to M1 and inhibited tumor growth and vascularization in a mouse colon carcinoma model [233].”
Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Yan, P., Klingbiel, D., Saridaki, Z., Ceppa, P., Curto, M., McKee, T. A., Roth, A., Tejpar, S., Delorenzi, M., Bosman, F. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0939 · Cited by 78 · cited 1×
“Loss of p53 causes defects in DNA damage response and DNA repair, leading to genomic instability [12], whereas loss of SMAD4 impacts cell proliferation and differentiation pathways and is associated with CRC progression [17].”
Sasaki, K., Tsuno, N. H., Sunami, E., Kawai, K., Hongo, K., Hiyoshi, M., Kaneko, M., Murono, K., Tada, N., Nirei, T., et al. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328353f8c7 · Cited by 76 · cited 1×
“Several studies demonstrated that inhibiting autophagy by treatment with chloroquine or hydroxychloroquine, which are repurposed anti-malarial drugs, increased the sensitivity of CRC cells to 5-FU, oxaliplatin, and chemoradiotherapy [149–151].”
Chi, X., Yang, P., Zhang, E., Gu, J., Xu, H., Li, M., Gao, X., Li, X., Zhang, Y., Xu, H., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2361 · Cited by 75 · cited 1×
“Several antigens being evaluated as candidates for anti-CRC CAR-T cell therapy have shown efficacy in CRC preclinical models, including carcinoembryonic antigen and guanylyl cyclase 2C [227,228].”
Zhao, X., Pan, J., Li, W., Yang, W., Qin, L., & Pan, Y. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s176928 · Cited by 75
Chen, J.-F., Luo, X., Xiang, L.-S., Li, H.-T., Zha, L., Li, N., He, J.-M., Xie, G.-F., Xie, X., & Liang, H.-J. (2106) · Oncotarget · doi:10.18632/oncotarget.9236 · Cited by 74 · cited 1×
“For instance, targeting enzymes like Enhancer of Zeste Homologue 2 (EZH2; subunit of HMT that trimethylates H3K27) has shown promising inhibitory effects on proliferation, migration, invasion, and colony/sphere formation of CRC cell lines [169,170].”
Schonewolf, C. A., Mehta, M., Schiff, D., Wu, H., Haffty, B. G., Karantza, V., & Jabbour, S. K. (2014) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v6.i3.74 · Cited by 71 · cited 1×
“Several studies demonstrated that inhibiting autophagy by treatment with chloroquine or hydroxychloroquine, which are repurposed anti-malarial drugs, increased the sensitivity of CRC cells to 5-FU, oxaliplatin, and chemoradiotherapy [149–151].”
Chen, Y., Chen, M., & Deng, K. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5472 · Cited by 71 · cited 1×
“There is also a substantial amount of preclinical data supporting the use of Wnt pathway inhibitors in various types of cancer including CRC, and some of these agents are in different stages of clinical research [194].”
Handali, S., Moghimipour, E., Kouchak, M., Ramezani, Z., Amini, M., Angali, K. A., Saremy, S., Dorkoosh, F. A., & Rezaei, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.030 · Cited by 71 · cited 1×
“Similarly, folic acid-targeted 5-FU-loaded liposomes were demonstrated to have greater efficacy in CRC cells in vitro and in vivo compared to liposomal 5-FU or free drug [116,117].”
Yu, C., Luo, D., Yu, J., Zhang, M., Zheng, X., Xu, G., Wang, J., Wang, H., Xu, Y., Jiang, K., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02077-w · Cited by 70 · cited 1×
“However, while MEK inhibitors have shown clinical efficacy in several types of KRAS -mutated cancers, preclinical studies in CRC revealed that treatment with MEK inhibitor alone was not very effective in KRAS -mutated CRC cells due to different mechanisms of acquired resistance [123–125].”
Farkas, S. A., Vymetalkova, V., Vodickova, L., Vodicka, P., & Nilsson, T. K. (2014) · Epigenomics · doi:10.2217/epi.14.7 · Cited by 67 · cited 1×
“Alterations in DNA methylation have been identified in genes that are frequently mutated in CRC and in genes involved in DNA repair and the Wnt/ β -catenin pathway [24].”
A Review on the Special Radiotherapy Techniques of Colorectal Cancer
Tam, S. Y., & Wu, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00208 · Cited by 67 · cited 1×
“…given as a combination of two or three chemotherapy drugs, such as FOLFOX, FOLFIRI, FOLFIRINOX, or CAPOX (acronyms for the di ff erent components in each combination). external beam radiation therapy (EBRT), internal radiation therapy (brachytherapy), or intraoperative radiation therapy (IORT) [32].”
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67 · cited 2×
“Abnormal or poorly organized tumor vasculature also results in hypoxia, which stabilizes hypoxia-inducible factor (HIF) transcription factors that activate signaling pathways regulating survival, angiogenesis, and metabolism [85].”
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
Zhou, S., Peng, J., Xiao, L., Zhou, C., Fang, Y., Ou, Q., Qin, J., Liu, M., Pan, Z., & Hou, Z. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03734-4 · Cited by 66 · cited 1×
“Targeting EZH2 may also be an effective strategy to overcome oxaliplatin resistance, since EZH2 was shown to promote oxaliplatin resistance in CRC cells, while EZH2 inhibitor suppressed tumor growth and sensitized CRC cells to oxaliplatin [172,173].”
Recent advances in targeted drug delivery systems for resistant colorectal cancer
Sharifi-Azad, M., Fathi, M., Cho, W. C., Barzegari, A., Dadashi, H., Dadashpour, M., & Jahanban-Esfahlan, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02605-y · Cited by 65
Shelton, J. W., Waxweiler, T. V., Landry, J., Gao, H., Xu, Y., Wang, L., El-Rayes, B., & Shu, H.-K. G. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.015 · Cited by 62
Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022) · Cancers · doi:10.3390/cancers14194874 · Cited by 62 · cited 3×
“Defective cell cycle checkpoints allow CRC cells to bypass damage-induced arrest and proceed through the cell cycle with damaged DNA [50].”
Role of the tumor microenvironment in cancer hallmarks and targeted therapy (Review)
Naser, R., Fakhoury, I., El‑Fouani, A., Abi‑Habib, R., & El‑Sibai, M. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5471 · Cited by 61 · cited 2×
“Non-cellular components include the ECM—composed of proteins, proteoglycans, and glycoproteins— cytokines, growth factors, and enzymes like proteases [82].”
Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications
Cao, Q., Tian, Y., Deng, Z., Yang, F., & Chen, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063358 · Cited by 60 · cited 2×
“Moreover, alterations in histone acetylation and methylation can lead to changes in KRAS expression, and H3K9 and H3K27 methylation can repress EGFR transcription, thus leading to resistance against cetuximab [55].”
Chen, L., Yang, F., Chen, S., & Tai, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.995882 · Cited by 60 · cited 1×
“…repurposed drugs like metformin and NSAIDs, as well as natural products such as curcumin, salvianolic acid, and vitamin C are being studied for their ability to target colorectal CSC self-renewal, proliferation, apoptosis, and ROS pathways and help overcome therapy resistance [148,210].”
Meisenberg, C., Ashour, M. E., El-Shafie, L., Liao, C., Hodgson, A., Pilborough, A., Khurram, S. A., Downs, J. A., Ward, S. E., & El-Khamisy, S. F. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1026 · Cited by 59 · cited 2×
“…various studies suggest that inhibiting HDACs can overcome resistance to chemotherapy-induced DNA damage in CRC cells by different molecular mechanisms, such as downregulating thymidylate synthase gene expression or modifying chromatin condensation, and subsequently inducing cell death [58,59,165].”
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem
Vaghari-Tabari, M., Majidinia, M., Moein, S., Qujeq, D., Asemi, Z., Alemi, F., Mohamadzadeh, R., Targhazeh, N., Safa, A., & Yousefi, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118255 · Cited by 58
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58 · cited 1×
“Reduced drug influx is a common mechanism of resistance, often resulting from decreased expression of transporters responsible for drug uptake, such as membrane solute carrier (SLC) family proteins [43].”
Nanoparticles: Attractive tools to treat colorectal cancer
Younis, N. K., Roumieh, R., Bassil, E. P., Ghoubaira, J. A., Kobeissy, F. H., & Eid, A. H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.006 · Cited by 58 · cited 1×
“Research is ongoing to examine the utility of biocompatible NPs, such as metal-based NPs, carbon-based NPs, polymeric NPs, and liposomes, as drug delivery tools to treat CRC [108,109].”
A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Park, W.-J., & Kim, M. J. (2023) · Cells · doi:10.3390/cells12081110 · Cited by 57 · cited 1×
“Additionally, recently developed technologies are currently being explored to inhibit Wnt signaling, such as proteolysis-targeting chimeras and molecular glue degraders, antibody–drug conjugates, and antisense oligonucleotides [195].”
Methylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57 · cited 2×
“DNMT inhibitors include cytidine analogs that incorporate into DNA (e.g., azacitidine and decitabine) and non-nucleoside inhibitors that directly interact with DNMTs [158].”
Zhang, X., Ma, Y., Ma, J., Yang, L., Song, Q., Wang, H., & Lv, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.913669 · Cited by 57 · cited 1×
“Furthermore, inducing ferroptosis could also be used to target CRC DTPs, as GPX4 and ferrous iron were upregulated in 5-FU-tolerant persister cells, which were sensitive RSL3-induced ferroptosis in xenograft tumor models [155].”
Liu, B., & Wang, H. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11321 · Cited by 56 · cited 1×
“Additionally, erastin, a selective inhibitor of SLC7A11 (a cystine–glutamate antiporter also known as xCT) exhibited a synergistic effect in inducing ferroptosis in CRC cells when combined with oxaliplatin [156].”
Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
Quagliano, A., Gopalakrishnapillai, A., & Barwe, S. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00992 · Cited by 56 · cited 1×
“Epigenetic alterations in CRC cells can also mediate therapy resistance through interactions with components of the TME, including immune cells, stromal cells, and extracellular matrix (ECM) proteins [65].”
Pitts, T. M., Newton, T. P., Bradshaw-Pierce, E. L., Addison, R., Arcaroli, J. J., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Purkey, A., Tentler, J. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113037 · Cited by 54 · cited 1×
“Indeed, results from several preclinical and clinical studies indicate that dual pharmacological targeting of MAPK and PI3K pathways may be an effective strategy to inhibit the growth of CRC cells, regardless of KRAS or PI3K mutational status [127–131].”
Zhuang, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08108-9 · Cited by 54 · cited 4×
“Loss-of-function mutations in the tumor suppressor genes TP53 (mutated in 50–60% of CRCs) and SMAD4 (mutated in ~15% of CRCs) also occur frequently [13,16].”
InfluentialHistone modifications as a pathogenic mechanism of colorectal tumorigenesis
Gargalionis, A. N., Piperi, C., Adamopoulos, C., & Papavassiliou, A. G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.05.002 · Cited by 53
Autophagy Regulation on Cancer Stem Cell Maintenance, Metastasis, and Therapy Resistance
Wang, X., Lee, J., & Xie, C. (2022) · Cancers · doi:10.3390/cancers14020381 · Cited by 53 · cited 1×
“Moreover, inhibiting autophagy could also target therapy-resistant CSCs and DTPs, both of which often have upregulated autophagy pathways [80,152].”
Flis, S., Gnyszka, A., & Flis, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092305 · Cited by 53 · cited 1×
“For instance, multiple DNMT inhibitors exhibited additive or synergistic effects when combined with 5-FU, oxaliplatin or irinotecan in CRC cell lines [159–161].”
El Hallal, R., Lyu, N., & Wang, Y. (2021) · Molecules · doi:10.3390/molecules26030567 · Cited by 51 · cited 1×
“For instance, gold nanoparticles have been used to effectively deliver various anti-CRC therapies to tumor cells, including chemotherapy drugs and anti-EGFR inhibitors, resulting in enhanced anticancer drug efficacy [110–112].”
Deng, L., Jiang, N., Zeng, J., Wang, Y., & Cui, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.733270 · Cited by 51 · cited 1×
“…approaches are currently being investigated for their potential to specifically target CAFs, including a variety of inhibitors, agonists, and neutralizing antibodies that interfere with different molecules or signaling pathways that contribute to the supportive role of CAFs in the TME [224].”
Guillén Díaz-Maroto, N., Sanz-Pamplona, R., Berdiel-Acer, M., Cimas, F. J., García, E., Gonçalves-Ribeiro, S., Albert, N., Garcia-Vicién, G., Capella, G., Moreno, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3957 · Cited by 51
Histone Lysine Methylation Dynamics Control EGFR DNA Copy-Number Amplification
Clarke, T. L., Tang, R., Chakraborty, D., Van Rechem, C., Ji, F., Mishra, S., Ma, A., Kaniskan, H. Ü., Jin, J., Lawrence, M. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0463 · Cited by 50 · cited 1×
“Furthermore, targeting KDM4 (demethylase for H3K9 and H3K36) may be used to overcome cetuximab resistance in CRC with high EGFR gene copy number, since inhibiting KDM4 reduced EGFR amplifications in CRC cells [175].”
Lima-Fernandes, E., Murison, A., da Silva Medina, T., Wang, Y., Ma, A., Leung, C., Luciani, G. M., Haynes, J., Pollett, A., Zeller, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09309-4 · Cited by 50
Self-citationKamrani, A., Nasiri, H., Hassanzadeh, A., Ahmadian Heris, J., Mohammadinasab, R., Sadeghvand, S., Sadeghi, M., Valedkarimi, Z., Hosseinzadeh, R., Shomali, N., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01430-8 · Cited by 50 · cited 3×
“Another emerging type of immunotherapy is oncolytic virus therapy, which uses oncolytic viruses to selectively kill tumor cells while sparing healthy cells [185].”
InfluentialRed flag symptoms: detailed account of clinicopathological features in young-onset colorectal cancer
Riaz, R., Masood, N., & Benish, A. (2017) · Intestinal Research · doi:10.5217/ir.2017.15.2.203 · Cited by 49 · cited 1×
“Right-sided CRC is associated with younger age, and common signs and symptoms include diarrhea, bowel obstruction, and constipation, whereas left-sided CRC is more common in older patients, who often present with rectal bleeding and bowel obstruction [10,11].”
Modarai, S. R., Gupta, A., Opdenaker, L. M., Kowash, R., Masters, G., Viswanathan, V., Zhang, T., Fields, J. Z., & Boman, B. M. (2018) · Oncotarget · doi:10.18632/oncotarget.26157 · Cited by 49
To, K. K. W., Poon, D. C., Wei, Y., Wang, F., Lin, G., & Fu, L.-W. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.034 · Cited by 49
Bourhis, J., Stein, A., Paul de Boer, J., Van Den Eynde, M., Gold, K. A., Stintzing, S., Becker, J. C., Moran, M., Schroeder, A., Pennock, G., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102172 · Cited by 47 · cited 1×
“For instance, several clinical studies are evaluating ICIs and the anti-EGFR mAb cetuximab as a therapeutic combination in CRC since cetuximab can modulate the immune composition of the TME, potentially making cancer cells more susceptible to ICIs [240].”
Fotsitzoudis, C., Koulouridi, A., Messaritakis, I., Konstantinidis, T., Gouvas, N., Tsiaoussis, J., & Souglakos, J. (2022) · Cancers · doi:10.3390/cancers14184394 · Cited by 46 · cited 2×
“Cancer-associated fibroblasts (CAFs) support CRC growth, proliferation, invasion, and metastasis and promote angiogenesis and immune remodeling [91].”
Autophagy: A Versatile Player in the Progression of Colorectal Cancer and Drug Resistance
Manzoor, S., Muhammad, J. S., Maghazachi, A. A., & Hamid, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924290 · Cited by 45 · cited 4×
“Autophagy is a distinct form of programmed cell death (type II) that involves degradation of cellular organelles and recycling the components [53].”
InfluentialTargeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44 · cited 3×
“Various preclinical studies have demonstrated PARP inhibitors to also be effective in CRC cells; however, the sensitivity may depend on the status of certain genes involved in DDR [132].”
InfluentialCheng, X., Zhao, F., Ke, B., Chen, D., & Liu, F. (2023) · Cancers · doi:10.3390/cancers15215209 · Cited by 44 · cited 3×
“…in drug metabolism contribute to resistance, with CRC cells increasing the inactivation or degradation of drugs through upregulated expression of enzymes like glutathione S-transferases (GSTs), uridine 5 ′ -diphospho-glucuronosyltransferases (UGTs), and cytochrome P450 (CYP) enzymes [46,47].”
Ishiguro, M., Iida, S., Uetake, H., Morita, S., Makino, H., Kato, K., Takagi, Y., Enomoto, M., & Sugihara, K. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9285-4 · Cited by 43 · cited 1×
“For instance, multiple DNMT inhibitors exhibited additive or synergistic effects when combined with 5-FU, oxaliplatin or irinotecan in CRC cell lines [159–161].”
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers · doi:10.3390/cancers13051031 · Cited by 43 · cited 2×
“Different types of anti-angiogenic agents are used to block the VEGF-VEGFR signaling axis, including mAbs (bevacizumab, ramucirumab), soluble decoy receptors (ziv-aflibercept), and small molecule multi-kinase inhibitors (regorafenib) [35].”
CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer
Sato-Dahlman, M., Miura, Y., Huang, J. L., Hajeri, P., Jacobsen, K., Davydova, J., & Yamamoto, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18340 · Cited by 43
MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells
Liang, H., Xu, Y., Zhang, Q., Yang, Y., Mou, Y., Gao, Y., Chen, R., Chen, C., & Dai, P. (2019) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2019.1569530 · Cited by 43 · cited 1×
“On the other hand, miR-483-3p is downregulated in oxaliplatin-resistant CRC cells, and miR-483-3p mimics restored oxali-platin responsiveness via increased apoptosis [179].”
Ikehata, M., Ogawa, M., Yamada, Y., Tanaka, S., Ueda, K., & Iwakawa, S. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00574 · Cited by 42
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42 · cited 5×
“Defective DDR can also cause changes in the TME by releasing inflammatory cytokines, which create an immunosuppressive state that helps CRC cells evade immune surveillance, thereby reducing the effectiveness of immunotherapies [51].”
InfluentialInsights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death
Kopecka, J., Godel, M., Dei, S., Giampietro, R., Belisario, D. C., Akman, M., Contino, M., Teodori, E., & Riganti, C. (2020) · Cells · doi:10.3390/cells9041033 · Cited by 41 · cited 2×
“Recent research has revealed substantial posttranscriptional gene regulation of ABC transporters by miRNAs, underscoring the potential utilization of novel bioengineered miRNA agents to down-regulate ABC transporter expression and affect intracellular drug accumulation [101].”
Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise
Abd, G. M., Laird, M. C., Ku, J. C., & Li, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1227884 · Cited by 41
Liu, T., Wang, X., Hu, W., Fang, Z., Jin, Y., Fang, X., & Miao, Q. R. (2019) · Neoplasia · doi:10.1016/j.neo.2019.03.011 · Cited by 41 · cited 1×
“Alterations in histone modifications can regulate gene expression and chromatin structure, further contributing to resistance against chemotherapy drugs [57–59].”
Yu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40 · cited 3×
“The most common ICIs are PD-1 inhibitors (e.g., pembrolizumab, nivolumab) and CTLA-4 inhibitors (e.g., ipilimumab), which activate T cells to induce an antitumor response from the immune system (Figure 2) [38].”
Perspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39 · cited 1×
“Furthermore, hypoxia promotes self-renewal by activation of Wnt and Notch signaling pathways and embryonic stem cell transcription factors, and it modulates differentiation of tumor cells and tumor-associated stromal cells [86–88].”
Ghasemi Toudeshkchouei, M., Zahedi, P., & Shavandi, A. (2020) · Materials · doi:10.3390/ma13071483 · Cited by 39 · cited 1×
“Polymeric polylactide-co-glycolic acid (PLGA) NPs were also shown to increase the cytotoxicity of chemotherapy drugs, such as 5-FU and irinotecan, in CRC cell lines [113,114].”
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Tria, S. M., Burge, M. E., & Whitehall, V. L. J. (2023) · Cancers · doi:10.3390/cancers15082375 · Cited by 38 · cited 1×
“There are additional drugs currently in development for targeting G12C, G12V, or other mutations (e.g., G12D), as well as non-selective, multi-KRAS mutant inhibitors (active against G12C, G12D, G12V, and G12X) [121].”
Ravizza, R., Molteni, R., Gariboldi, M. B., Marras, E., Perletti, G., & Monti, E. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.021 · Cited by 38 · cited 1×
“Moreover, HIF-1 inhibitors have been shown to enhance the sensitivity of CRC cells to the cytotoxic effects of chemotherapy drugs like 5-FU and oxaliplatin [212–214].”
YANG, G., JIANG, O., LING, D., JIANG, X., YUAN, P., ZENG, G., ZHU, J., TIAN, J., WENG, Y., & WU, D. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3890 · Cited by 38
Lee, D. H., Won, H.-R., Ryu, H.-W., Han, J. M., & Kwon, S. H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4405 · Cited by 38 · cited 1×
“Additionally, a selective inhibitor of HDAC6 was reported to enhance the chemotherapeutic effects of 5-FU or oxaliplatin in CRC cells [167,168].”
Alzoubi, S., Brody, L., Rahman, S., Mahul-Mellier, A.-L., Mercado, N., Ito, K., El-Bahrawy, M., Silver, A., Boobis, A., Bell, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9887 · Cited by 37 · cited 1×
“…various studies suggest that inhibiting HDACs can overcome resistance to chemotherapy-induced DNA damage in CRC cells by different molecular mechanisms, such as downregulating thymidylate synthase gene expression or modifying chromatin condensation, and subsequently inducing cell death [58,59,165].”
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · cited 3×
“Immune checkpoint inhibitors (ICIs) are a class of immunotherapy that is often used to treat MSI High (MSI-H) or dMMR tumors [37].”
Zhang, Y., Liu, X., Zhang, J., Xu, Y., Shao, J., Hu, Y., Shu, P., & Cheng, H. (2020) · Aging · doi:10.18632/aging.102929 · Cited by 37 · cited 1×
“Similarly, inhibition of miR-19a or miR-454-3p, which are upregulated in oxaliplatin-resistant cells and target PTEN gene expression, partially reversed oxaliplatin resistance in CRC cell lines [177,178].”
PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan
Emami, J., Maghzi, P., Hasanzadeh, F., Sadeghi, H., Mirian, M., & Rostami, M. (2018) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2017.1340950 · Cited by 36 · cited 1×
“Polymeric polylactide-co-glycolic acid (PLGA) NPs were also shown to increase the cytotoxicity of chemotherapy drugs, such as 5-FU and irinotecan, in CRC cell lines [113,114].”
Tan, Y., Zhang, S., Zhu, H., Chu, Y., Zhou, H., Liu, D., & Huo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.48 · Cited by 35 · cited 1×
“Additionally, a selective inhibitor of HDAC6 was reported to enhance the chemotherapeutic effects of 5-FU or oxaliplatin in CRC cells [167,168].”
Engaging plasticity: Differentiation therapy in solid tumors
Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35 · cited 1×
“Differentiation therapy uses agents such as retinoic acid to induce CSCs to differentiate into less tumorigenic cells, making them unable to sustain tumor growth and potentially more susceptible to other therapies [204].”
Ravindranathan, P., Pasham, D., & Goel, A. (2019) · Carcinogenesis · doi:10.1093/carcin/bgy184 · Cited by 35
miR-133b down-regulates ABCC1 and enhances the sensitivity of CRC to anti-tumor drugs
Chen, M., Li, D., Gong, N., Wu, H., Su, C., Xie, C., Xiang, H., Lin, C., & Li, X. (2017) · Oncotarget · doi:10.18632/oncotarget.17677 · Cited by 35 · cited 1×
“Moreover, several studies have demonstrated that using miRNA mimics to increase the levels of specific miRNAs, such as miR-133b, miR-142-3p, miR-297, and miR-522, can increase the chemosensitivity of drug-resistant CRC cells [104–107].”
Zhang, X., Wen, L., Chen, S., Zhang, J., Ma, Y., Hu, J., Yue, T., Wang, J., Zhu, J., Bu, D., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1155-9 · Cited by 35
MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer
Qian, X.-L., Zhou, F., Xu, S., Jiang, J., Chen, Z.-P., Wang, S.-K., Zuo, Y., & Ni, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638537 · Cited by 34 · cited 1×
“Similarly, inhibition of miR-19a or miR-454-3p, which are upregulated in oxaliplatin-resistant cells and target PTEN gene expression, partially reversed oxaliplatin resistance in CRC cell lines [177,178].”
Koehler, B. C., Scherr, A., Lorenz, S., Elßner, C., Kautz, N., Welte, S. E., Jaeger, D., Urbanik, T., & Schulze‐Bergkamen, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106571 · Cited by 34 · cited 1×
“For example, drugs targeting the BCL-2 family of proteins, such as BH3 mimetics, have been investigated for their ability to induce apoptosis in CRC cells [142,143].”
The combination of olaparib and camptothecin for effective radiosensitization
Miura, K., Sakata, K.-I., Someya, M., Matsumoto, Y., Matsumoto, H., Takahashi, A., & Hareyama, M. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-62 · Cited by 33
(2007) · PubMed · Cited by 33
Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies
Miller, E. D., Hitchcock, K. E., & Romesser, P. B. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00900-5 · Cited by 31 · cited 1×
“While most CRC patients initially respond to therapy, the overall response rate to first-line treatments can vary widely, depending on the patient tumor characteristics and treatment regimen [39].”
Golubovskaya, V., Sienkiewicz, J., Sun, J., Huang, Y., Hu, L., Zhou, H., Harto, H., Xu, S., Berahovich, R., Bodmer, W., et al. (2023) · Cancers · doi:10.3390/cancers15102860 · Cited by 31 · cited 1×
“For example, EpCAM/CD3 BiTEs eliminated CSCs in colon cancer cell lines and primary CSCs isolated from colon cancer patient samples and blocked CRC xenograft tumor growth [186,187].”
Cited by
Kantha, A., Das, D., Pai, E., Kumar, T., & Pandey, M. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04117-1 · Cited by 28
“…found in CMS1, the BEACON regimen—which consists of cetuximab, binimetinib, and encorafenib—has also demonstrated efficacy in treating BRAF-mutant mCRC. Adjuvant chemotherapy is not clearly linked to improved overall survival in CMS1 malignancies as compared to standard chemotherapy ([53]– [54]).”
Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance
Han, J., Liang, W., & Li, K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1753180 · Cited by 21
“Drug resistance can be intrinsic, present at diagnosis, or acquired during treatment, often leading to tumor recurrence and metastasis (Haynes and Manogaran, 2025; Oktavianda and Giselvania, 2024).”
Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications
Peshin, S., Bashir, F., Kodali, N. A., Dharia, A. A., Zaiter, S., Singal, S., & Moka, N. (2025) · Antibodies · doi:10.3390/antib14030058 · Cited by 18
“Alternatively, VEGF inhibitors like bevacizumab or novel LAG-3 inhibitors may help overcome resistance by modulating the tumor microenvironment [57,58].”
Shahsavani, M. B., Heidari, M., Yousefi, R., & Moosavi‐Movahedi, A. A. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70208 · Cited by 14
“…share chal- lenges—dose-limiting toxicities, nonspecific cytotoxicity, and multifactorial drug resistance arising from enhanced DNA repair, decreased uptake, or increased efflux (Galluzzi et al. 2012; Dilruba and Kalayda 2016; Haynes and Manogaran 2025; Richardson et al. 2023; Matsuo et al. 2010).”
Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances
Chen, Y., Zhang, J., Ding, Y., Zhu, F., & Chen, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00433-4 · Cited by 17
“Drug resistance is a critical, multimechanistic challenge in cancer treatment, involving both endogenous and exogenous factors [314].”
Metadata
- Authors
- Haynes, J., & Manogaran, P.
- Affiliations
- Marshall University (US)
- Corresponding author
- Haynes, Jennifer
- ORCID
- Manogaran, Prasath
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-02-25
- Volume
- 26
- Issue
- 5
- Pages
- 1988
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11901061
- OpenAlex
- W4407920293
- Cited by
- 82
- References
- 249
- Citations by year
- 2026: 57 · 2025: 24
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- colorectal cancer, drug resistance, resistance mechanisms, epigenetic modifications, tumor heterogeneity, tumor microenvironment, drug transporters, DNA damage response, cell death pathways, cancer stem cells, signaling pathways, therapeutic target
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplastic Stem Cells, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Epigenesis, Genetic, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.